Table 2 Comparison of brainstem symptoms between anti-AQP4 (+) and anti-AQP4 (-) patients with ABS
Onset symptoms | Anti-AQP4 (+) | Anti-AQP4 (-) | Total | P value |
|---|---|---|---|---|
n = 14 | n = 17 | n = 31 | ||
Diplopia | 6/14 (42.86Â %) | 8/17 (47.06Â %) | 14/31 (45.16Â %) | 0.551 |
Area postrema clinical syndrome | 10/14 (71.43Â %) | 3/17 (17.65Â %) | 13/31 (41.94Â %) | 0.004 |
 Intractable hiccup | 5/14 (29.41 %) | 1/17 (5.88 %) | 6/31 (19.35 %) | 0.05 |
 Nausea and vomiting | 9/14 (64.28 %) | 3/17 (17.65 %) | 12/31 (38.71 %) | 0.011 |
Bulbar dysfunction | 5/14 (35.71Â %) | 6/17 (35.29Â %) | 11/31 (35.48Â %) | 0.636 |
 Dysarthria | 1/14 (7.14 %) | 3/17 (17.65 %) | 4/31 (12.90 %) | 0.378 |
 Dysphagia | 2/14 (14.29 %) | 4/17 (23.53 %) | 6/31 (19.35 %) | 0.429 |
 Alalia | 2/14 (14.29 %) | 0/17 (0 %) | 2/31 (6.45 %) | 0.196 |
Vertigo | 4/14 (28.57Â %) | 7/17 (41.18Â %) | 11/31 (35.48Â %) | 0.364 |
Facial paralysis | 2/14 (14.29Â %) | 5/17 (29.41Â %) | 7/31 (22.58Â %) | 0.287 |
Ataxia | 3/14 (21.43Â %) | 7/17 (41.18Â %) | 7/31 (22.58Â %) | 0.218 |
Quadriplegia | 2/14 (14.29Â %) | 1/17 (5.88Â %) | 3/31 (9.68Â %) | 0.425 |